drugset / Trial / NCT05509933
Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.
Timeline
- Start
- 2022-11-09
- Primary completion
- 2027-12-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Budesonide | Small molecule | — | — |